Novelties in Melanoma Research: Immunotherapy, Targeted Therapy

Speaker: Olivier Alan Michielin

O. Michielin discusses the findings presented in melanoma track at ECC2015. For each of the selected abstracts, he elaborates a rationale of the study and preliminary findings. He covers combination of talimogene laherparepvec and pembrolizumab for unresectable advanced melanoma, PD1 inhibition-induced changes and associated immune infiltrate, as well as early study that combined CDK4/6 and MEK inhibitors in NRAS mutated melanoma.

Discussion Points:

  • Abstract #LBA 24 presented at ECC 2015: Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma 
  • Abstract #3305 presented at ECC 2015: PD1 inhibition-induced changes in melanoma and its associated immune infiltrate
  • Abstract #3300 presented at ECC 2015: A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS‐mutant melanoma